Healthline

Dosage Details for Dovato

Dovato (dolutegravir/lamivudine) is a prescription drug that’s used to treat HIV. The drug comes as a tablet that you swallow. It’s usually taken once per day ...
Monthly Prescribing Reference

Dovato Use Expanded to Include Virologically Suppressed Adults With HIV-1

Previously, Dovato was only approved for treatment-naïve adults. The Food and Drug Administration (FDA) has expanded the approval of Dovato (dolutegravir/lamivudine ...
FiercePharma

GSK's Dovato matches Gilead's HIV juggernaut Biktarvy with less weight gain in Spanish trial

In HIV treatment, Gilead Sciences’ popular Biktarvy serves as a benchmark for newer drugs to overcome. In a new head-to-head study, GSK’s two-drug regimen Dovato showed comparable antiviral efficacy ...
FiercePharma

Can new Dovato data jump-start uptake of 2-drug HIV regimen? ViiV hopes so

Previous clinical results for ViiV Healthcare’s vaunted two-drug HIV regimens have yet to pose a big threat to chief rival Gilead Sciences. But the GlaxoSmithKline joint venture aims to change that ...
Yahoo Finance

ViiV Healthcare shares results from trial of Dovato and three-drug therapy for HIV

UK-based pharmaceutical company ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine (DTG/3TC ...
Yahoo Finance

ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Monthly Prescribing Reference

Dovato Approved for Treatment-Naïve Patients With HIV-1 Infection

The Food and Drug Administration (FDA) has approved Dovato (dolutegravir and lamivudine; Viiv Healthcare) as a complete regimen for the treatment of HIV-1 infection in treatment-naïve adults with no ...
Reuters

GSK's two-drug HIV Dovato treatment meets main goal in study

(Reuters) - GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a ...
PharmaTimes

ViiV posts positive long-term data for two-drug HIV regimen Dovato

Dovato demonstrated non-inferior efficacy compared to TAF-based regimens GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the ...
Nasdaq

ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of ...

The 48-week data from the phase III SALSA study represent a diverse patient population, and demonstrate comparable safety for 2-drug regimen Dovato versus continuation of a current antiretroviral ...
PharmaTimes

ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato

PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens ViiV Healthcare has announced new 96‑week findings from a sub‑group analysis of the PASO DOBLE study, ...